HC Wainwright Issues Negative Estimate for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Harrow in a research note issued on Wednesday, March 4th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.16) per share for the quarter, down from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q2 2026 earnings at $0.10 EPS and FY2026 earnings at $0.54 EPS.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.23). The business had revenue of $89.09 million during the quarter, compared to analysts’ expectations of $88.42 million. Harrow had a positive return on equity of 36.51% and a negative net margin of 1.89%.

HROW has been the subject of several other reports. Zacks Research cut shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. LADENBURG THALM/SH SH increased their price objective on Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. William Blair restated an “outperform” rating on shares of Harrow in a report on Tuesday. Finally, Cantor Fitzgerald lowered their target price on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Harrow currently has a consensus rating of “Moderate Buy” and an average target price of $71.14.

Harrow Trading Up 0.5%

HROW stock opened at $36.35 on Friday. Harrow has a 12 month low of $20.85 and a 12 month high of $54.85. The firm’s 50-day moving average is $47.65 and its 200 day moving average is $43.69. The company has a market capitalization of $1.35 billion, a PE ratio of -213.81 and a beta of 0.05. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.52.

Institutional Investors Weigh In On Harrow

Several institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC increased its position in shares of Harrow by 13.1% during the fourth quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock worth $120,000 after purchasing an additional 284 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after purchasing an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after buying an additional 341 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Harrow by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock valued at $3,428,000 after buying an additional 376 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Harrow reported record 2025 results and set a 2026 outlook, which supports the company’s growth narrative and may underpin investor confidence in longer‑term revenue momentum. Article Title
• Positive Sentiment: Management will present at the Leerink Partner’s 2026 Global Healthcare Conference, giving Harrow visibility to institutional investors and analysts — a potential catalyst for renewed interest. Article Title
• Neutral Sentiment: Coverage piece analyzes Harrow’s valuation after mixed Q4 results and flags 2026 profitability concerns — useful context for investors weighing near‑term earnings risk vs. longer‑term growth. Article Title
• Negative Sentiment: HC Wainwright cut multiple 2026 EPS estimates across quarters and the full year (Q1 to -$0.16 from $0.02; Q2 to $0.10 from $0.25; Q3 to $0.20 from $0.29; Q4 to $0.40 from $0.51; FY2026 to $0.54 from $1.08). Although the firm retains a “Buy” rating and $70 target, the downward revisions signal near‑term profit pressure and are a clear headwind for the stock.
• Negative Sentiment: Analyst sentiment weakened elsewhere: Zacks downgraded Harrow from “Hold” to “Strong Sell,” which can amplify selling pressure from retail/quantitative strategies. Article Title Article Title
• Negative Sentiment: Market reports noted shares gapped down after disappointing quarterly earnings, indicating investors reacted negatively to the results and guidance versus expectations. Article Title

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.